Testing for Genotoxic Impurities: How Low Should We Go?
Patient safety is a paramount concern for the pharmaceutical industry. Overlooked toxicity liability could not only put patient safety at risk, but also have huge financial implications for a pharmaceutical company. Dr. Fenghe Qiu, Principle Scientist & Leader of the Trace Analysis Group at Boehringer Ingelheim, spoke to Pharma IQ about managing the risk of genotoxic impurity.
To continue reading this story
Please note: That all fields marked with an asterisk (*) are required.